Lineage Switch at Relapse of Childhood Acute Leukemia: A Report of Four Cases by Park, Meerim et al.
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Lineage Switch at Relapse of Childhood Acute Leukemia:  
A Report of Four Cases
Lineage switch in acute leukemia is an uncommon event at relapse, and therefore rarely 
reported in the literature. Here, we have described the clinical laboratory features of four 
cases in which the cell lineage switched from acute lymphoblastic leukemia (ALL) to acute 
myeloid leukemia (AML). One patient was initially diagnosed with B-ALL, switched to T-ALL 
at the first relapse, and eventually, AML at the second relapse. A lineage switch 
represented either relapse of the original clone with heterogeneity at the morphologic level 
or emergence of a new leukemic clone. Further sequential phenotypic and cytogenetic 
studies may yield valuable insights into the mechanisms of leukemic recurrence, with 
possible implications for treatment selection.
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“Lineage switch” is the term used to describe the phenomenon 
of acute leukemia that meets standard French-American-Brit-
ish (FAB) criteria for a specific lineage (lymphoid or myeloid) at 
initial diagnosis, but converts to the opposite lineage upon re-
lapse (1). This situation rarely occurs, and prognosis is variable. 
Although different hypotheses have been proposed to explain 
the occurrence of lineage switch, the specific causative factors 
have not yet to be identified. Here, we present the clinical and 
laboratory features of four cases in which the cell lineage 




A 15-month-old boy was diagnosed with pro-B cell ALL L1 in June 
2001. Immunophenotypic analysis revealed CD19+ and HLA-
DR+. Cytogenetic analysis showed 46, XY. The patient achieved 
complete remission (CR) after induction chemotherapy, and 
completed chemotherapy in January 2005. Thirty-three months 
after completion of therapy, the patient presented with fever and 
cervical lymph node enlargement. Bone marrow (BM) analysis 
revealed 87.0% small-to-medium-sized leukemic blasts with a 
moderate amount of cytoplasm. Cytochemical and immunocy-
tochemical staining revealed a negative reaction for myeloper-
oxidase (MPO) and anti-MPO. Flow cytometric analysis showed 
positivity for CD33, cyCD13, cyCD33, and CD117. Data support-
ed the diagnosis of AML M0. Cytogenetic analysis showed 46, 
XY, t(9;11)(p22;q23). Fluorescence in situ hybridization (FISH) 
analysis with a MLL-probe showed a signal in 97.5% of blasts. 
AML-directed reinduction therapy was initiated and the patient 
achieved a second CR at the end of this period with no evidence 
of MLL gene arrangement. The patient subsequently underwent 
allogeneic hematopoietic stem cell transplantation (allo-HSCT), 
and remained in CR for 36 months.
Case 2
A 6-yr-old boy was diagnosed with B-lineage common cell ALL 
L1 in March 2003. Immunophenotypic analysis revealed HLA-
DR, TdT, CD10, CD19 and CD22 positivity. Cytogenetic analysis 
showed 56, XY, +X, +Y, +Y, +4, +8, +10, +14, +17, -20, +21, +21, 
+21[6]/57, idem, +Y[19]. After induction chemotherapy, the pa-
tient achieved CR. During chemotherapy, at 9 months after the 
initial diagnosis, the patient presented fever with pancytopenia. 
BM revealed a homogeneous population of large blasts with 
abundant basophilic cytoplasm. Cytochemical staining revealed 
positivity for MPO and α-naphthyl-butyrate esterase (ANBE). 
Blasts were positive for HLA-DR, CD13, CD14, and CD33. Cyto-
genetic analysis showed 46, XY, t(8;16)(p11.2;p13.1). The patient 
was re-diagnosed with AML M4, and achieved a second remis-Park M, et al.  •  Lineage Switch in Acute Leukemia
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sion after salvage therapy. Due to lack of available donors for 
HSCT, chemotherapy was continued for 2 yr. The patient has 
remained in CR for 79 months since the second remission.
Case 3
A 7-yr-old girl was diagnosed with B lineage ALL L2 in May 1999. 
A BM study revealed 89% of blasts showing medium-sized nuclei 
with some nuclear indentation or cleavage. Immunophenotypic 
analysis revealed positivity for HLA-DR, cytoplasmic IgM with 
aberrant CD33. Cytochemical staining showed a block-dot pos-
itive reaction for Periodic Acid Schiff (PAS) and a negative for 
MPO and nonspecific esterase (NSE). Immunocytochemistry 
was negative for anti-MPO. The 46, XX karyotype was identified. 
After induction chemotherapy, the patient achieved CR. Dur-
ing chemotherapy, at 14 months after diagnosis, the patient pre-
sented with prolonged fever. BM study revealed 68.2% leukemic 
lymphoblasts. Cytochemical staining data were similar to those 
at initial diagnosis. However, immunophenotypic analysis show-
ed positivity for CD2, CD5, CD7, CD34, and HLA-DR with aber-
rant CD33, indicating that the relapse was T cell ALL. Cytoge-
netic analysis showed trisomy 13. At 45 days after the initiation 
of ALL reinduction therapy, the patient showed relapse, that was 
identified AML M1. Cytochemical staining revealed a coarse 
granular pattern for PAS, and negativity for MPO and ANBE. 
Immunocytochemistry revealed positivity for anti-MPO. Im-
munophenotypic staining showed positiivity for CD13, CD33, 
CD34 and HLA-DR with aberrant CD7. The patient received 
AML-directed chemotherapy, but did not achieve CR, and died 
of disease progression 9 months after AML relapse.
Case 4
A 3-month-old girl was diagnosed with pre-B cell ALL L1 in De-
cember 2008. BM revealed small-to-medium sized lymphoblasts 
comprising 92.4% of all nucleated cells. Immunochemical stain-
ing showed PAS+, MPO-, and ANBE-. Flow cytometric analysis 
revealed positivity for CD19, CD34, and TdT with aberrant CD33. 
Cytogenetic studies showed t(4;11)(q21;q23), which was further 
confirmed by FISH analysis. After induction chemotherapy, BM 
analysis revealed morphologic CR, however, FISH with the MLL-
probe showed a signal in 5.5%. During chemotherapy, 2 months 
after initial diagnosis, the patient relapsed as AML M4. Blasts 
were positive for CD2, CD13, CD14, CD33, CD41, and CD65. 
FISH with the MLL probe showed a signal in 2%. Cytochemical 
staining showed positivity for MPO and ANBE. The patient un-
derwent allo-HSCT four months after AML-directed chemo-
therapy. She remained in remission for 17 months following 
the second CR. 
DISCUSSION
All the cases reported here were initially diagnosed as ALL, but 
relapsed as AML. In the first three cases, the original karyotype 
had been replaced by an entirely different abnormal karyotype, 
while in case 4, lineage switch represented a relapse of the same 
leukemic clone. 
  In case 1, the patient was initially diagnosed as ALL L1 with 
normal karyotype, which switched to AML M0 with t(9;11) at 
relapse with complete immunophenotypic changes. In chemo-
therapy-associated secondary AML, which has a mean latency 
period of 2 yr, monocytic subtypes are more common and as-
sociated with translocations involving the MLL gene on 11q23 
(2). Considering the long duration between diagnosis and re-
lapse and the multiple antineoplastic drugs administered to the 
patient before relapse, we cannot conclude the effect of that che-
motherapy for the relapse with clonal change. 
  In case 2, ALL L1 switched to AML M4, with loss of CD10 and 
TdT. In terms of gain or loss of phenotypic markers at relapse   
of acute leukemia, one of the most common changes is loss of 
CD10 and/or TdT activity (3-5). Pui et al. (3) previously suggest-
ed that loss of CD10 might be related to malignant transforma-
tion of pluripotent stem cells after eradication of the original stem 
cell line with chemotherapy, but the precise significance of this 
finding remains unknown. AML-t(8;16), diagnosed at relapse, 
is characterized by monocytic differentiation of AML M4/M5 
and poor prognosis. The t(8;16) gene fuses the MOZ gene encod-
ing histone acetytransferase located on 8p11 with the CBP gene, 
which also encodes histone acetyltransferase located on 16p13. 
Recent reports have indicated that the chimeric transcription of 
MOZ-CBP is essential for leukemogenesis (5). The majority of 
the documented AML-t(8;16) cases are de novo, and, to the best 
of our knowledge, 12 cases of secondary t(8;16) leukemia (in-
cluding our case 2) have been reported to date (6-8). However, 
the relationship between histone acetylase and secondary leu-
kemia is yet to be determined.
  In case 3, the original diagnosis was B-ALL with aberrant ex-
pression of the myeloid marker, CD33. At first relapse, the pa-
tient showed immature T-lymphoid phenotype of CD7+, CD4-, 
CD8-, CD1-, retaining CD 33 expression, in addition to the emer-
gence of a new clone, trisomy 13. Finally, the patient switched 
to AML retaining aberrant T-lymphoid cell marker CD7. Triso-
my 13, observed in our patient at relapse, is associated with un-
differentiated or biphenotypic acute leukemia, and is rarely de-
scribed in lymphocytic disorders (9). The first transformation of 
B-ALL was T-lineage ALL coexpressing myelocytic and undiffer-
entiated markers, such as CD33 and CD34. A subset of hemato-
poietic precursors that lack mature T-cell and myeloid antigens 
retains the potential to differentiate into T-lymphoid and myeloid 
cells. Hurshfield and co-workers (10) described the in vivo con-
version of CD7+, CD4-, CD8- lymphoid cells to the myeloid lin-
eage, while Kurtzberg et al. (11) suggested that CD7+, CD4-, CD8- 
leukemias arise from immature hematopoietic stem cells with 
lineage infidelity. Moreover, several authors have proposed that Park M, et al.  •  Lineage Switch in Acute Leukemia
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NOTCH1 mutations occur in leukemic stem cells that precede 
both myeloid and T-lineage commitment (12). Considering the 
rapid lineage switch between the first and second relapse and 
early immature T-lymphoid phenotype in case 3, we suggest that 
lineage switch may arise from very immature cells belonging to 
a common T-cell/myeloid progenitor. 
  Lineage switch in infant leukemia has been previously de-
scribed in the literatures (13, 14). The most common chromo-
somal abnormality reported in infant leukemia is t(4;11) (15). 
Rearrangement of the MLL gene is known to play an important 
role in leukemogenesis (16). Some authors have suggested that 
the MLL gene rearrangement occurs in B lymphocyte-mono-
cyte bipotential stem cells (13). Although the prognosis of MLL-
infant leukemia is poor (15), our patient 4 remained in CR after 
allo-HSCT.
  Lineage switch may be regarded as a variation of mixed-lin-
eage leukemia in which the lineage at onset is converted to an-
other at a later time (17). However, the relationship between lin-
eage switch and mixed-lineage leukemia is yet to be determined. 
In some cases, lineage switch may be part of the biologic spec-
trum of mixed-lineage leukemia. An example of this is the pa-
tients 3 and 4, who met the morphologic and cytochemical cri-
teria for diagnosis of ALL, but displayed positivity for CD33 with 
the expanded immunophenotype panel.
  In conclusion, although our current findings are insufficient 
to confirm the mechanism of lineage switch, each case indicates 
different possibilities. Sequential phenotypic and cytogenetic 
studies may yield valuable insights into the mechanisms of leu-
kemic recurrence, with possible implications for individualized 
treatment selection.
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